The bile alcohol 5β-scymnol ([24R]-(+)-5β-cholestan-3α,7α,12α,24,26,27-hexol) is a therapeutic nutraceutical derived from marine sources, however very little is known about its potential for biotransformation as a xenobiotic in higher vertebrates. In this study, biotransformation products of scymnol catalysed by liver microsomes isolated from normal and streptozotocin (STZ)-treated male Wistar rats were characterised by liquid chromatography-tandem mass spectroscopy (LC-MSMS). In order of increasing polarity relative to the reversed phase sorbent, structural assignments were made for four biotransformation products, namely 3-oxoscymnol (5β-cholestan-3-one-7α,12α,24,26,27-pentol); 7-oxoscymnol (5β-cholestan-7-one-3α,12α,24,26,27-pentol); 3β-scymnol (5β-cholestan-3β,7α,12α,24,26,27-hexol) and 6β-hydroxyscymnol (5β-cholestan-3α,6β,7α,12α,24,26,27-heptol). In addition, a total of eight biotransformation products were characterised from microsomal incubations of crude oxoscymnol compounds, namely 7β-scymnol; 3,12-dioxoscymnol; 3,7-dioxoscymnol; 7,12-dioxoscymnol; 12-oxo-3β-scymnol; 7-oxo-3β-scymnol; 6β-hydroxy-12-oxoscymnol and 6β-hydroxy-7-oxoscymnol. Collectively, the results indicate hepatic enzyme-catalysed hydroxylation, dehydrogenation and epimerisation reactions on the steroid nucleus of scymnol, and provide an insight into biotransformation pathways for scymnol use as a therapeutic nutraceutical in higher vertebrates.
Read full abstract